Image by Игорь Левченко from Pixabay

The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of the munKNEE Pure-Play Marijuana Drug Stocks Index and the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which out-performed last week? This article has the answer. Here are the details:

One hundred clinical-stage psychedelic drug stocks now trade on North American stock exchanges. 60 of the stocks research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 35 Companies Researching Them): psilocybin (AKA "magic" mushrooms), psilocybin truffles (AKA "magic" truffles), ketamine (AKA "the date rape drug"), DMT, Ibogaine, LSD (AKA "acid"), MDMA (AKA "ecstasy"), mescaline (AKA "peyote) and 5-MeO-DMT (AKA "toad"); 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know).

The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $50M but less than $500M and only 16 of the 100 psychedelic drug stocks meet that criteria. The remaining 84 stocks in the Index have market caps below $50M or are above $500M. The latter include ATAI, Compass Pathways, Mind Medicine, and GH Resources and they are not included in the index given their very large market caps and high share prices which would have dominated the index's performance. (All currency amounts are in U.S. dollars. Go here to convert to another currency.)

The munKNEE Pure-Play Marijuana-Based Drug Stocks Category

The 8 marijuana-based clinical-stage stocks

• were UP +13.7% last week and
• are now only DOWN -1.8% YTD,
• ranged in price from $0.03/share to $4.45/share (an average of $1.26/share) as of Friday,
• and have an average market capitalization of $104M.

Those that changed in price by +/- 5% last week are presented below in descending order including YTD percentage movements:

1. Enveric (ENVB): was UP +45.3% last week but is still DOWN -38.3% YTD
2. Allied Corp. (ALID): was UP +9.7% and is now UP +50.7% YTD
3. Zynerba (ZYNE): was UP +7.2% and is now UP +34.8% YTD

The munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Category

The 8 psychedelic compound-based clinical-stage stocks

• were DOWN -0.2% last week but are still UP +51.6% YTD
• range in price from $0.18/share to $5.75/share (an average of $1.72/share) as of last Friday,
• and have an average market capitalization of $200M.

Those that changed in price by +/- 5% last week are presented below in descending order including YTD percentage movements:

1. Awakn Life (AWKNF): was UP +15.1% last week and is now UP +8.1% since beginning to trade on June 23rd
2. Cybin (CYBN): was DOWN -12.6% but is still UP 76.0% YTD
3. Red Light Holland (TRUFF): was DOWN -14.3% and is now DOWN -28.0% YTD

In Summary

In answer to the opening question as to which Index out-performed last week the answer is:

• the Marijuana-Based Drug Stocks Index was UP +13.7% last week and is now only DOWN -1.8% YTD
• the Psychedelic Compounds-Based Index was DOWN -0.2% last week but is still UP +51.6% YTD

In combined total:

• the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index was UP +4.4% last week and is now UP +21.2% YTD

For those interested, my previous article, American and Canadian Cannabis Stocks Were Flat Last Week, asked whether the LP or MSO sub-category out-performed last week so go there for the answer.